Hansoh Pharmaceutical Group Company Limited

SEHK:3692 Rapport sur les actions

Capitalisation boursière : HK$108.7b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Hansoh Pharmaceutical Group Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Huijuan Zhong

Directeur général

CN¥14.8m

Rémunération totale

Pourcentage du salaire du PDG49.6%
Durée du mandat du directeur général8.7yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction8.4yrs
Durée moyenne du mandat des membres du conseil d'administration6.8yrs

Mises à jour récentes de la gestion

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Aug 07
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Jul 16
If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23
Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01
Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28
Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04
There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Dec 08
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Oct 12
Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

Sep 14
Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 10
Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Jun 11
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jan 23
Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Dec 01
Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Oct 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Aug 28
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Jun 09
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

May 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

Apr 22
Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Feb 06
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price

Nov 07
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Oct 11
Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 14
A Look At The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Analyse de la rémunération des PDG

Comment la rémunération de Huijuan Zhong a-t-elle évolué par rapport aux bénéfices de Hansoh Pharmaceutical Group?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2023CN¥15mCN¥7m

CN¥3b

Sep 30 2023n/an/a

CN¥3b

Jun 30 2023n/an/a

CN¥3b

Mar 31 2023n/an/a

CN¥3b

Dec 31 2022CN¥11mCN¥5m

CN¥3b

Sep 30 2022n/an/a

CN¥3b

Jun 30 2022n/an/a

CN¥3b

Mar 31 2022n/an/a

CN¥3b

Dec 31 2021CN¥16mCN¥8m

CN¥3b

Rémunération vs marché: La rémunération totale de Huijuan ($USD 2.07M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 859.20K ).

Rémunération et revenus: La rémunération de Huijuan a augmenté de plus de 20 % au cours de l'année écoulée.


PDG

Huijuan Zhong (63 yo)

8.7yrs

Titularisation

CN¥14,807,000

Compensation

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Huijuan Zhong
Chairlady8.7yrsCN¥14.81mpas de données
Aifeng Lyu
Executive Director8.4yrsCN¥9.39m0.023%
CN¥ 25.5m
Yuan Sun
Executive Director8.7yrsCN¥16.63m0.021%
CN¥ 22.9m
Min Hu
VP & CFOno datapas de donnéespas de données
Chih-Hung Lee
Chief of Science Officer2.3yrspas de donnéespas de données
Chuanhe Xu
Senior Vice President15.4yrspas de donnéespas de données
Weiyong Sun
Chief Commercial Officerno datapas de donnéespas de données
Shengli Zhong
Joint Company Secretary & Senior VP6yrspas de donnéespas de données
Sze Wai Tam
Joint Company Secretaryless than a yearpas de donnéespas de données

8.4yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 3692 est chevronnée et expérimentée (ancienneté moyenne 8.4 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Huijuan Zhong
Chairlady8.7yrsCN¥14.81mpas de données
Aifeng Lyu
Executive Director8.4yrsCN¥9.39m0.023%
CN¥ 25.5m
Yuan Sun
Executive Director8.7yrsCN¥16.63m0.021%
CN¥ 22.9m
Guoqiang Lin
Independent Non-Executive Director5.3yrsCN¥360.00kpas de données
Sheung Wai Chan
Independent Non-Executive Director5.3yrsCN¥360.00kpas de données
Dongtao Yang
Independent Non-Executive Director5.3yrsCN¥360.00kpas de données

6.8yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 3692 sont considérés comme expérimentés (ancienneté moyenne 6.8 ans).